Relationship Between Using Fibrate and Open-Angle Glaucoma in Hyperlipidemic Patients: A Population-Based Cohort Study

Overview

Journal Int J Environ Res Public Health

Publisher MDPI

Specialties Environmental Health
Public Health

Date 2022 Feb 25

PMID 35206602

Authors

Yung-En Tsai

Yi-Hao Chen

Chien-An Sun

Chi-Hsiang Chung

Wu-Chien Chien

Ke-Hung Chien

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the associated risk between using fibrate and open-angle glaucoma (OAG) in hyperlipidemic patients from the National Health Insurance Research Database (NHIRD).

Methods: We collected data over a 16-year period from the NHIRD, and used the Fisher's exact test and Pearson chi-square test to analyze variables. Adjusted hazard ratios (aHR) were used to examine the risk factors for disease development. We applied Kaplan-Meier analysis to compare the cumulative incidence of OAG.

Results: A total of 10,011 patients using fibrate were enrolled in the study cohort, and 40,044 patients not using fibrate were enrolled in the control cohort. The incidence of OAG was lower in the study cohort than in the control cohort (aHR = 0.624, = 0.007). The overall incidence of OAG was 463.02 per 100,000 person-years in the study cohort and 573.65 per 100,000 person-years in the control cohort. We used the Kaplan-Meier method to calculate the cumulative risk of developing OAG. The results revealed that after using fibrate for over seven years, the study cohort had a greatly lower rate of developing OAG than the control cohort (log-rank test = 0.050).

Conclusions: Our studies showed that using fibrate for over seven years may lead to a lower risk of OAG in patients with hyperlipidemia. Nevertheless, further prospective studies that comprehensively investigate the relationship between using fibrate and OAG are needed.

Citing Articles

Tocolytic Treatment for the Prevention of Preterm Birth from a Taiwanese Perspective: A Survey of Taiwanese Obstetric Specialists.

Lee H, Yeh C, Yang S, Liu C, Chen Y, Wang P Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409902 PMC: 8998907. DOI: 10.3390/ijerph19074222.

References

Munoz de Escalona-Rojas J, Cantero-Hinojosa J, Garrido-Pareja F, Garcia-Serrano J, Padilla-Torres J . [Hemodynamic component in glaucoma and its association with risk factors and cardiovascular disease]. Med Clin (Barc). 2013; 143(4):157-60. DOI: 10.1016/j.medcli.2013.07.026. View

Marrs J, ROWE Jr K . The effect of clofibrate on open-angle glaucoma. Arch Ophthalmol. 1969; 82(1):19-20. DOI: 10.1001/archopht.1969.00990020021005. View

Park S, Byun S, Park J, Kim M . Primary Open-angle Glaucoma and Increased Risk of Chronic Kidney Disease. J Glaucoma. 2019; 28(12):1067-1073. DOI: 10.1097/IJG.0000000000001390. View

Kersten S . Peroxisome proliferator activated receptors and lipoprotein metabolism. PPAR Res. 2008; 2008:132960. PMC: 2220040. DOI: 10.1155/2008/132960. View

Kuang T, Xirasagar S, Kao Y, Shia B, Lin H . Association of Systemic Hypertension With Primary Open-angle Glaucoma: A Population-based Case-Control Study. Am J Ophthalmol. 2020; 218:99-104. DOI: 10.1016/j.ajo.2020.04.020. View

Escandon P, Vasini B, Whelchel A, Nicholas S, Matlock H, Ma J . The role of peroxisome proliferator-activated receptors in healthy and diseased eyes. Exp Eye Res. 2021; 208:108617. PMC: 8594540. DOI: 10.1016/j.exer.2021.108617. View

Gupta M, Khosla P, Garg K . Evaluation of effects of clofibrate, an antilipaemic agent on intraocular pressure in experimental glaucoma. Indian J Ophthalmol. 1985; 33(5):313-5. View

Bogdanov P, Hernandez C, Corraliza L, Carvalho A, Simo R . Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes. Acta Diabetol. 2014; 52(1):113-22. DOI: 10.1007/s00592-014-0610-2. View

Wu T, Majeed A, Kuo K . An overview of the healthcare system in Taiwan. London J Prim Care (Abingdon). 2015; 3(2):115-9. PMC: 3960712. DOI: 10.1080/17571472.2010.11493315. View

10.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J . Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98(19):2088-93. DOI: 10.1161/01.cir.98.19.2088. View

11.

Jung Y, Han K, Park H, Park C . Type 2 diabetes mellitus and risk of open-angle glaucoma development in Koreans: An 11-year nationwide propensity-score-matched study. Diabetes Metab. 2017; 44(4):328-332. DOI: 10.1016/j.diabet.2017.09.007. View

12.

Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M . PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 2006; 34(Pt 6):1341-6. DOI: 10.1042/BST0341341. View

13.

Chen Y, Hu H, Chu D, Chen H, Chang C, Chou P . Patients with Primary Open-Angle Glaucoma May Develop Ischemic Heart Disease More Often than Those without Glaucoma: An 11-Year Population-Based Cohort Study. PLoS One. 2016; 11(9):e0163210. PMC: 5029879. DOI: 10.1371/journal.pone.0163210. View

14.

Chan E, Li X, Tham Y, Liao J, Wong T, Aung T . Glaucoma in Asia: regional prevalence variations and future projections. Br J Ophthalmol. 2015; 100(1):78-85. DOI: 10.1136/bjophthalmol-2014-306102. View

15.

Wang S, Bao X . Hyperlipidemia, Blood Lipid Level, and the Risk of Glaucoma: A Meta-Analysis. Invest Ophthalmol Vis Sci. 2019; 60(4):1028-1043. DOI: 10.1167/iovs.18-25845. View

16.

Jung Y, Han K, Park H, Lee S, Park C . Metabolic Health, Obesity, and the Risk of Developing Open-Angle Glaucoma: Metabolically Healthy Obese Patients versus Metabolically Unhealthy but Normal Weight Patients. Diabetes Metab J. 2020; 44(3):414-425. PMC: 7332336. DOI: 10.4093/dmj.2019.0048. View